Month: June 2022

NEUSPERA MEDICAL® ANNOUNCES SECOND PHASE OF SANS-UUI IDE CLINICAL TRIAL WITH THE NUVELLA™ SYSTEM

06/22/2022

Pivotal trial to study the safety and efficacy of sacral nerve stimulation in patients with urinary urgency incontinence symptoms Excerpt from the Press Release: SAN JOSE, Calif., June 14, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial…

Read More

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL

06/21/2022

Excerpt from the Press Release: SAN DIEGO, June 14, 2022 /PRNewswire/ — HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF). Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with…

Read More

Research suggests specialized brain imaging can unveil mysteries of Alzheimer’s disease, other disorders

06/21/2022

Excerpt from the Press Release: Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and disability in older adults. Though advances have been made in understanding the harrowing brain disease, diagnostic tests are currently limited and there are no treatments. Now, a uOttawa Faculty of Medicine assistant professor and a…

Read More

Entrepreneurial spirit shines brightly for young CEO helping people with limited mobility in their hands

06/21/2022

At 22, with her degree from McMaster’s program in Integrated Biomedical Engineering and Health Sciences in hand, Lianna Genovese already holds two patents in the United States and Canada, as well as four trademarks. Excerpt from the Press Release: Passion, drive and a good idea turned Lianna Genovese into a corporate entrepreneur long before she…

Read More

Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines

06/20/2022

Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS)…

Read More

Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

06/20/2022

• PBML04 represents the company’s fourth program to receive IND clearance Excerpt from the Press Release: PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared…

Read More

Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

06/20/2022

First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell…

Read More

ORYZON Announces FDA Orphan Drug Designation Granted to Iadademstat for Treatment of Small Cell Lung Cancer

06/17/2022

Excerpt from the Press Release: Now has orphan drug designation for SCLC and AML MADRID, Spain and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and…

Read More

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

06/17/2022

Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio, Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy – – Acceptable Safety Profile, Supporting Continued Clinical Development – – Full Results to Be Presented at Future Medical Congress –…

Read More

Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group

06/17/2022

Excerpt from the Press Release: SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma. The ASCEND trial is a 125-patient, double-blind, randomized, placebo-controlled clinical…

Read More